The mechanistic role of tirzepatide in atherosclerosis: A review.

Atherosclerosis is the leading cause of death worldwide, characterized by progressive deposition of lipids, fibrous elements, and calcification in the large arteries. The pathophysiology of atherosclerosis is complex and related to diverse mechanisms. Prominently, obesity, type 2 diabetes (T2D), and associated inflammation are common modifiable risk factors implicated in the pathogenesis of atherosclerosis. Henceforth, targeting of obesity, T2D, and linked inflammation may reduce risk for the development and progression of atherosclerosis. Researchers have demonstrated that tirzepatide, a recently approved drug for managing obesity and T2D, can reduce inflammatory changes in atherosclerosis. Nevertheless, the fundamental mechanism of tirzepatide against atherosclerosis is not completely clarified. Consequently, this review aims to discuss the mechanism of tirzepatide against atherosclerosis.